Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Loïck Vidot

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Pharmaceutical Statistics|July 2, 2024
Futility Interim Analysis Based on Probability of Success Using a Surrogate EndpointRonan Fougeray, Loïck Vidot, Marco Ratta, et al.
BMC Cancer|January 28, 2023
Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapyJulien Taieb, Timothy Price, Loïck Vidot, et al.
Future Oncology (London, England)|August 30, 2022
Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT TurkeyAhmet Özet, Faysal Dane, Nuri Faruk Aykan, et al.
The New England Journal of Medicine|May 3, 2023
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal CancerGerald W Prager, Julien Taieb, Marwan Fakih, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|July 2, 2024
Futility Interim Analysis Based on Probability of Success Using a Surrogate EndpointRonan Fougeray, Loïck Vidot, Marco Ratta, et al.
BMC Cancer|January 28, 2023
Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapyJulien Taieb, Timothy Price, Loïck Vidot, et al.
Future Oncology (London, England)|August 30, 2022
Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT TurkeyAhmet Özet, Faysal Dane, Nuri Faruk Aykan, et al.
The New England Journal of Medicine|May 3, 2023
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal CancerGerald W Prager, Julien Taieb, Marwan Fakih, et al.
Pageof 1